Prostate Cancer Stocks List

Recent Signals

Date Stock Signal Type
2019-10-16 ABBV Narrow Range Bar Range Contraction
2019-10-16 ABBV NR7 Range Contraction
2019-10-16 ABBV Bollinger Band Squeeze Range Contraction
2019-10-16 ADMP Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-16 ADMP Lower Bollinger Band Walk Weakness
2019-10-16 ADMP 1,2,3 Retracement Bearish Bearish Swing Setup
2019-10-16 ADMP New 52 Week Low Weakness
2019-10-16 ADXS Narrow Range Bar Range Contraction
2019-10-16 ADXS 20 DMA Support Bullish
2019-10-16 ADXS NR7 Range Contraction
2019-10-16 AYTU 20 DMA Support Bullish
2019-10-16 AYTU Pocket Pivot Bullish Swing Setup
2019-10-16 AYTU Crossed Above 50 DMA Bullish
2019-10-16 BLCM Lizard Bullish Bullish Day Trade Setup
2019-10-16 BLCM Hammer Candlestick Bullish
2019-10-16 CBLI Volume Surge Other
2019-10-16 CBLI Lower Bollinger Band Walk Weakness
2019-10-16 CBLI New Downtrend Bearish
2019-10-16 CBLI New 52 Week Closing Low Bearish
2019-10-16 CBLI Wide Range Bar Range Expansion
2019-10-16 CBLI New 52 Week Low Weakness
2019-10-16 CBLI Expansion Breakdown Bearish Swing Setup
2019-10-16 EDAP Pocket Pivot Bullish Swing Setup
2019-10-16 EPIX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-10-16 EPIX 1,2,3 Pullback Bullish Bullish Swing Setup
2019-10-16 EPIX Boomer Buy Setup Bullish Swing Setup
2019-10-16 EPIX Calm After Storm Range Contraction
2019-10-16 HARP NR7 Range Contraction
2019-10-16 HARP Narrow Range Bar Range Contraction
2019-10-16 HARP Bollinger Band Squeeze Range Contraction
2019-10-16 HARP Stochastic Reached Oversold Weakness
2019-10-16 INO Pocket Pivot Bullish Swing Setup
2019-10-16 INO Stochastic Reached Overbought Strength
2019-10-16 INO Wide Range Bar Range Expansion
2019-10-16 INO Crossed Above 50 DMA Bullish
2019-10-16 INO Expansion Pivot Buy Setup Bullish Swing Setup
2019-10-16 IONS Fell Below 20 DMA Bearish
2019-10-16 IONS Expansion Pivot Sell Setup Bearish Swing Setup
2019-10-16 ISR Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-16 ISR Narrow Range Bar Range Contraction
2019-10-16 MYGN Stochastic Reached Overbought Strength
2019-10-16 MYGN Pocket Pivot Bullish Swing Setup
2019-10-16 MYOV Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-16 MYOV Boomer Buy Setup Bullish Swing Setup
2019-10-16 MYOV Narrow Range Bar Range Contraction
2019-10-16 NLNK Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-16 OPK Doji - Bearish? Reversal
2019-10-16 OPK Shooting Star Candlestick Bearish
2019-10-16 OPK Bollinger Band Squeeze Range Contraction
2019-10-16 OPK 20 DMA Resistance Bearish
2019-10-16 PDSB Stochastic Reached Oversold Weakness
2019-10-16 PDSB Narrow Range Bar Range Contraction
2019-10-16 PGNX NR7-2 Range Contraction
2019-10-16 PGNX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-10-16 PGNX Narrow Range Bar Range Contraction
2019-10-16 PGNX NR7 Range Contraction
2019-10-16 SLRX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-16 SLRX Bollinger Band Squeeze Range Contraction
2019-10-16 SLRX 20 DMA Support Bullish
2019-10-16 SNY 20 DMA Support Bullish
2019-10-16 SPHS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-16 SPHS 1,2,3 Retracement Bearish Bearish Swing Setup
2019-10-16 SPPI Pocket Pivot Bullish Swing Setup
2019-10-16 SPPI Crossed Above 50 DMA Bullish
2019-10-16 SPPI 20 DMA Resistance Bearish
2019-10-16 VERU 20 DMA Support Bullish

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

More about Prostate Cancer